首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1797410

双特异性抗体药物复合体的全球市场:临床试验，开发平台，竞争情形和市场机会(2025年)

Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球双特异性抗体-药物偶联物市场：临床试验、开发平台、竞争格局和市场机会 (2025) 研究结果和亮点

预计首批双特异性抗体-药物偶联物将于 2029 年上市
超过 100 种双特异性抗体-药物偶联物处于临床试验阶段
按公司、国家/地区及适应症及分阶段划分的双特异性抗体-药物偶联物临床试验洞察
中国在全球双特异性抗体药物偶联物开发领域占主导地位：超过 60 种偶联物
大多数用于治疗癌症的双特异性抗体-药物偶联物：超过 40 种
双特异性抗体-药物偶联物洞察抗体-药物偶联物开发平台
竞争格局

双特异性抗体-药物偶联物的需求及本报告的意义

双特异性抗体-药物偶联物 (BsADC) 代表了癌症治疗的新浪潮，它结合了双特异性抗体的特异性与传统抗体-药物偶联物 (ADC) 的靶向细胞毒性。传统 ADC 虽然有效，但往往受到脱靶毒性和肿瘤穿透性差的影响，尤其是在实体肿瘤中。 BsADC 透过同时靶向两种不同的抗原解决了这些问题。这种双重标靶性可以提高肿瘤选择性、改善药物传递并减少脱靶效应。随着技术的成熟，双特异性抗体-药物偶联物可望显着改善乳癌、肺癌和胰臟癌等难治性癌症患者的治疗效果。

本报告对双特异性抗体-药物偶联物进行了全面的市场分析，探讨了最新的临床试验动态、行业领袖、技术进步以及促成这些进步的合作伙伴关係。报告还深入分析了这些改进将如何影响癌症治疗的未来。

报告中临床试验的见解

临床试验在双特异性抗体-药物偶联物的开发中发挥核心作用，它决定了这些新疗法的安全性、有效性和耐受性。本报告分析了正在进行和即将进行的临床试验，并重点介绍了最有希望成为肿瘤领域下一代疗法的候选药物。例如，用于治疗EGFR突变非小细胞肺癌的双特异性ADC药物伊沙隆单抗布伦吉康（Iza-bren），目前正处于III期临床试验阶段，并已获得多项突破性疗法认定。本节提供的资讯具体涵盖了临床试验阶段、申办者、地理分布、技术提供者、合作方和许可证持有者。

各大公司积极参与双特异性抗体-药物偶联物的研发

双特异性抗体-药物偶联物市场竞争激烈，老牌製药公司以及专业化和新兴的生物技术公司都取得了长足的进步。阿斯特捷利康、安进、百时美施贵宝和信达生物等领先的研发公司正在积极开发用于治疗实体瘤的双特异性抗体-药物偶联物候选药物。这些公司不仅在改进现有的抗体偶联药物 (ADC) 技术，还在研究新的双特异性抗体形式，以提高特异性并减少副作用。

Duality Biotherapeutics、Allink Biotherapeutics 和江苏康宁杰瑞等专业化公司也在紧跟步伐，专注于突破性的平台和新颖的双特异性设计。随着这些公司开发差异化候选药物，双特异性抗体-药物偶联物领域的竞争日益激烈，各公司竞相抢占市场，力求率先推出强效疗法。

技术平台、合作与协议

双特异性抗体-药物偶联物的有效性取决于尖端技术平台，这些平台能够促进精准的抗体工程、有效的药物偶联以及更佳的肿瘤靶向性。像OmniAb和DualityBio这样的公司在创建促进双特异性抗体设计的创新平台方面处于领先地位。 OmniAb的抗体发现平台与Veraxa Biotech的ADC连接子技术的结合，反映了专注于合作的趋势，旨在最大限度地促进双特异性抗体-药物偶联物的开发。像百时美施贵宝和SystImmune这样的策略联盟正变得越来越普遍，各公司正在整合资源以加快开发速度。此类合作对于更快地将双特异性抗体偶联物推进到临床开发阶段至关重要，并且透过利用互补的技术，它们可以带来更有效的癌症治疗方案。

双特异性抗体-药物偶联物市场未来发展方向报告

本报告预测双特异性抗体-药物偶联物市场前景光明，技术进步和临床成功案例的累积将推动其强劲成长。研究团队将继续优化双特异性抗体-药物偶联物的设计，并专注于靶向肿瘤微环境中多种癌症抗原和路径的多标靶策略。金融投资也在推动市场朝着同一方向发展，反映出投资者对双特异性抗体-药物偶联物未来潜力日益增长的乐观态度。技术进步、合作伙伴关係和资金支持的协同作用使双特异性抗体-药物偶联物（BsADC）走在肿瘤学未来发展的前沿。

总体而言，随着有前景的疗法在临床试验中取得进展以及新技术的疗效不断提高，双特异性抗体-药物偶联物市场正处于显着增长的风口浪尖。本报告揭示了 BsADC 彻底改变癌症治疗的巨大潜力，并为以前无法治疗的癌症患者带来了新的希望。

First Bispecific Antibody Drug Conjugate Availability Expected By 2029
Insight On Bispecific Antibody Drug Conjugates In clinical Trials: > 100
Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
China Dominating Global Bispecific Antibody Drug Conjugates Development Landscape: > 60 Conjugates
Majority Of Bispecific Antibody Drug Conjugates Cancer: > 40
Insight On Bispecific Antibody Drug Conjugates Development Platforms
Competitive Landscape

Need for Bispecific Antibody-Drug Conjugate & Why This Report?

Bispecific antibody drug conjugates (BsADCs) are a new wave in cancer treatment, fusing the specificity of bispecific antibodies with the targeted cytotoxicity of traditional antibody drug conjugates (ADCs). Whereas classic ADCs have been effective, they tend to be hampered by off-target toxicity and reduced tumor penetration, especially in solid tumors. BsADCs solve these problems through the simultaneous targeting of two distinct antigens; this dual targeting allows for enhanced tumor selectivity, improved drug delivery, and fewer off-targeting effects. Bispecific antibody drug conjugates will go on to provide significant improvements in outcomes for patients, particularly those with hard-to-treat cancers such as breast, lung, and pancreatic cancers, as the technology matures.

This report offers an comprehensive market analysis of Bispecific antibody drug conjugates, discussing the most recent clinical trial updates, industry leaders, technological advancements, and collaborative partnerships shaping progress. It also offers insight into how such improvements are expected to impact cancer treatment in the future.

Clinical Trials Insight Included In Report

Clinical trials are central to the development of Bispecific antibody drug conjugates since they establish the safety, efficacy, and tolerability of these emerging treatments. This report explores the existing trend of ongoing and future clinical trials and highlights the most promising candidates in the pipeline that have the potential to be next-generation treatments in oncology. An example of this is Izalontamab brengitecan (Iza-bren), a bispecific ADC for EGFR-mutated NSCLC, in Phase 3 trials and already received several Breakthrough Therapy Designations. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders.

Major Companies Active In R&D of Bispecific Antibody Drug Conjugate

Bispecific antibody drug conjugates landscape is a highly competitive market with both well-established pharmaceutical companies and specialty and startup biotechs advancing strongly. Leaders such as AstraZeneca, Amgen, Bristol Myers Squibb, and Innovent Biologics are aggressively developing Bispecific antibody drug conjugates candidates to treat solid tumors. The players are not only refining current ADC technologies but also investigation of new bispecific antibody formats to enhance specificity and decrease side effects.

Specialty firms such as Duality Biotherapeutics, Allink Biotherapeutics, and Jiangsu Alphamab Biopharmaceuticals are not far behind, with a focus on groundbreaking platforms and novel bispecific designs. As these firms develop differentiated candidates, the competition in the bispecific antibody drug conjugates arena is becoming increasingly fierce, with companies racing to make the first-to-market with very potent therapies.

Technology Platforms, Collaborations & Agreements

The efficacy of bispecific antibody drug conjugates largely rests on state-of-the-art technology platforms that facilitate accurate antibody engineering, effective drug conjugation, and improved tumor targeting. Organizations such as OmniAb and DualityBio are at the forefront of creating innovative platforms to facilitate bispecific antibody design. OmniAb's antibody discovery platform paired with Veraxa Biotech's ADC linker technology captures the trend toward focused partnerships, with the intent of maximizing bispecific antibody drug conjugates development. Strategic alliances, such as that between Bristol Myers Squibb and SystImmune, are increasingly becoming prevalent as firms share resources to speed up development. These alliances are needed for accelerating BsADCs through clinical development more quickly, leveraging complementary skills to bring more potent cancer treatments.

Report Indicating Future Direction Of Bispecific Antibody Drug Conjugate Segment

The report foresees a rosy future for the bispecific antibody drug conjugates market, with strong growth fueled by advancing technology and mounting clinical success. Researchers are likely to continue to optimize bispecific antibody drug conjugates design, with an emphasis on multi-target strategies that target multiple cancer antigens or pathways of the tumor microenvironment. Financial investments are also propelling the market in the same direction, reflecting increased investor optimism about the future of bispecific antibody drug conjugates. The synergy of technological advancement, partnering relationships, and financial support places BsADCs at the forefront of the future of oncology.

Overall, the bispecific ADC market is on the cusp of huge growth, with promising treatments advancing through clinical trials and emerging technologies improving their effectiveness. This report shines a light on the promising potential of BsADCs to revolutionize cancer treatment and bring renewed hope for patients with previously untreatable cancers.

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates

1.1 Overview
1.2 Comparison With Other Immunotherapies

2. Need For Bispecific Antibody Drug Conjugates

3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action

3.1 General Structure & Design
3.2 Mechanism Of Action

4. Global Bispecific Antibody Drug Conjugate Market Insight

4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Bispecific Antibody Drug Conjugates Market Analysis by Region

5.1 China
5.2 US
5.3 Europe
5.4 South Korea

6. Bispecific Antibody Drug Conjugates - Application & Development By Indication

6.1 Breast Cancer
6.2 Gastrointestinal Cancer
6.3 Lung Cancer
6.4 Urologic Cancers
6.5 Gynecologic Cancers

7. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview

7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Phase

8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III

9. Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates

This Chapter Gives Comprehensive Insight On More Than 15 Platforms Technologies Used To Develop Bispecific Antibody Drug Conjugates

10. Competitive Landscape

10.1 Almac Discovery
10.2 Alphamab Oncology
10.3 Amgen
10.4 ArbeleBio
10.5 AstraZeneca
10.6 Beijing Biocytogen
10.7 BiVictriX Therapeutics
10.8 Bright Biologics
10.9 Corellia AI
10.10 CStone Pharmaceuticals
10.11 Debiopharm
10.12 Doma Bio
10.13 DualityBio
10.14 Enduring Biotech
10.15 Genmab
10.16 InduPro
10.17 Innovent Biologics
10.18 Kanaph Therapeutics
10.19 ProEn Therapeutics
10.20 Synaffix

简介目录图表

List of Figures

Figure 1-1: Future Directions In BsADC Development
Figure 1-2: Limitations Of Convectional Immunotherapies Addressable By BsADCs
Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate - General Mechanism of Action
Figure 4-1: Bispecific Antibody Drug Conjugate Market forecast - Projections For First 12 & 24 Months Post-Approval Of First Drug (US$ Million)
Figure 4-2: Key Future Opportunities
Figure 6-1: BL-B01D1-306 Phase III (NCT06343948) Study - Initiation & Estimated Completion Year
Figure 6-2: BL-B01D1-307 Phase III (NCT06382142) Study - Initiation & Estimated Completion Year
Figure 6-3: BL-B01D1-204-04 Phase II (NCT06471205) Study - Initiation & Estimated Completion Year
Figure 6-4: BL-B01D1-SI-B003-201-04 Phase II (NCT06042894) Study - Initiation & Estimated Completion Year
Figure 6-5: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study - Initiation & Estimated Completion Year
Figure 6-6: BL-B01D1-104 Phase I (NCT05470348) Study - Initiation & Estimated Completion Year
Figure 6-7: KM501-1001 Phase I (NCT05804864) Study - Initiation & Estimated Completion Year
Figure 6-8: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study - Initiation & Estimated Completion Year
Figure 6-9: BL-B01D1-103 Phase I (NCT05262491) Study - Initiation & Estimated Completion Year
Figure 6-10: BL-B01D1-302 Phase III (NCT06382129) Study - Initiation & Estimated Completion Year
Figure 6-11: BL-B01D1-301 Phase III (NCT06382116) Study - Initiation & Estimated Completion Year
Figure 6-12: BL-B01D1-304 Phase III (NCT06500026) Study - Initiation & Estimated Completion Year
Figure 6-13: DM001001 Phase II (NCT06475937) Study - Estimated Initiation & Estimated Completion Year
Figure 6-14: CIBI334A101 Phase I/II (NCT05774873) Study - Estimated Initiation & Estimated Completion Year
Figure 6-15: BL-B01D1-201 Phase II (NCT05785039) Study - Initiation & Estimated Completion Year
Figure 6-16: BL-B01D1-102 Phase I (NCT05393427) Study - Initiation & Estimated Completion Year
Figure 6-17: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study - Initiation & Estimated Completion Year
Figure 6-18: BL-B01D1-202 Phase Ib/II (NCT05803018) Study - Initiation & Estimated Completion Year
Figure 6-19: IMGN151-1001 Phase I (NCT05527184) Study - Initiation & Estimated Completion Year
Figure 6-20: JSKN003-102 Phase I/II (NCT05744427) Study - Initiation & Estimated Completion Year
Figure 7-1: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2025
Figure 7-2: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2025
Figure 7-3: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2025
Figure 7-4: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2025
Figure 9-1: ArbeleBio - Unnamed ADC Platform
Figure 9-2: BiVictriX - Bi-Cygni Therapeutics
Figure 9-3: Duality Biologics - DITAC Platform
Figure 9-4: Duality Biologics - DITAC Platform
Figure 9-5: LigaChem Biosciences - ConjuALL
Figure 9-6: LigaChem Biosciences - Conjugation Method
Figure 9-7: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-8: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-9: ProEn Therapeutics - ArtBody(TM) ADC technology
Figure 9-10: Synaffix - Proprietary Technologies

List of Tables

Table 1-1: BsADC vs. Conventional ADC
Table 1-2: Bispecific Antibody Formats
Table 4-1: Bispecific Antibody Drug Conjugate Market - Recent Collaborations
Table 6-1: BL-B01D1: Clinical Trials Underway For Lung Cancer

02-2729-4219

+886-2-2729-4219

License/价格

双特异性抗体药物复合体的全球市场:临床试验，开发平台，竞争情形和市场机会(2025年)

Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025

目录

第1章双特异性抗体药物复合体的构想与开发的现状

第2章双特异性抗体药物复合体的必要性

第3章双特异性抗体药物复合体- 设计和作用机制

第4章全球双特异性抗体药物复合体市场洞察

第5章双特异性抗体药物复合体市场分析，各地区

第6章双特异性抗体药物复合体- 各适应症的应用与开发

第7章全球双特异性抗体药物复合体的临床试验概要

第8章双特异性抗体药物复合体的临床试验:企业，国家，适应症，各相

第9章双特异性抗体药物复合体的开发所使用的平台技术

第10章竞争情形

Table of Contents